Skip to main content

Table 1 Baseline characteristics of the study participants

From: HIV-1 protease inhibitor drug resistance in Kenyan antiretroviral treatment-naive and -experienced injection drug users and non-drug users

Characteristic Non-drug users Injection drug users P
ART (−), n = 21 ART (+), n = 32 ART (−), n = 32 ART (+), n = 47
Female, n (%) 16 (76.2) 20 (62.5) 18 (56.3) 30 (63.8) 0.531
Age, years 36.0 (13.8) 35.2 (10.6) 30.1 (7.2)a 31.6 (7.4) 0.009
Duration (years) on ART, n (%)
 <1 0 (0.0) 3 (9.3) 0 (0.0) 20 (42.5)  
 1–3 0 (0.0) 7 (21.9) 0 (0.0) 24 (51.1)
 >3 0 (0.0) 22 (68.8) 0 (0.0) 3 (6.4)  
CD4+ T cell counts/ml 568 (673) 412 (554) 532 (472) 426 (423) 0.379
Log10 HIV-1 RNA, copies/ml 4.5 (2.8) 4.3 (1.6) 3.4 (2.7)a 3.5 (2.7)b 0.004
  1. Data are presented as medians (IQR, interquartile range) or indicated as number (n) and proportion (%) of subjects
  2. ART (−) anti-retroviral treatment-naive, ART (+) antiretroviral treatment-experienced, HIV-1 human immunodeficiency virus-1
  3. a P < 0.05 vs. ART (−) non-drug users
  4. b P < 0.01 vs. ART (−) non-drug users
  5. Significant P values are shown in italic